Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Jacobio Awarded China Breakthrough Status for KRAS Inhibitor in Pancreatic Cancer

publication date: Aug 10, 2023

Jacobio Pharma, a Beijing oncology company, reported its KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation in China as a second-line therapy for pancreatic cancer patients with a KRAS G12C mutation. The BTD was based on efficacy and safety data from ongoing glecirasib clinical trials. In late 2022, glecirasib was granted BTD for non-small cell lung cancer (NSCLC) patients with the KRAS G12C mutation, also as a second-line therapy. Jacobio has recently started a pivotal trial of glecirasib for pancreatic cancer, which the company says is the first global pancreatic cancer KRAS G12C registrational clinical study. More details....

Stock Symbol: (HK: 1167)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital